2Hoskins R E, Mannino S. Causality assessment of adverse drug reactions using decision support and informatics tools[J]. Pharmacoepidemiol Drug Saf, 1992, 1(5): 235-249.
3Arimone Y, Begaud B, Miremont-Salame G, et al. A new method for assessing drug causation provided agreement with experts' judgment[J]. J Clin Epidemiol, 2006, 59(3): 308-314.
4Venulet J. Aspects of standardization as applied to the assessment of drug-event associations[J].Drug Inf J, 1984,, 18(3-4): 199-210.
5Wiholm B E. The Swedish drug-event assessment methods. Special workshop regulatory[J].Drug Inf J, 1984, 18(3-4): 267-269.
6Jourde N, Mancini J, Chiche L. Azathioprine or methotrexate main- tenance for ANCA- associated vasculitis [ J ] . N Engl J Med, 2009,360 : 1358-1359.
8Noh JY, Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody ( MPO-AN- CA) in Graves'disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrino/( Oxf), 2001,54 (5) : 651-654.
9Harper L, Cockwen P, Savage CO. Case of propyhhiouraeil-in- duced ANCA associated small vessel vasculitis [ J]. Nephrol Dial Transplant, 1998,13:455-458.
10Dolman KM, Gans RO, Vervaat TJ, et al. Vaseulitis and antineu- trophil cytoplasmic autoantibodies associated with propylthiouraeil therapy [ J 1. Lancet, 1993,342:651-652.
